Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rozanolixizumab open-label extension in CIDP
NCT04051944Phase 2Completed
- Sponsor
- UCB
- Start
- Aug 2019
- Primary completion
- Nov 2021
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of rozanolixizumab in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), sponsored by UCB. Primary endpoint: Treatment-emergent Adverse Events at 84 weeks. Started Aug 2019; status: completed.
02
Drugs
rozanolixizumab
03
Conditions
chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
Beyond the preview
Go deeper on NCT04051944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04051944.